OBJECTIVE  To select Janus kinase(JAK) inhibitors, including Abrocitinib, Upadacitinib, and Baricitinib for the treatment of atopic dermatitis provides an evidence-based basis for the hospital policy-makers’ selection and clinical rational use.

METHODS  According to the A Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition), and referring to the drug instructions, clinical diagnosis and treatment guidelines and relevant literatures in Wanfang, VIP, CNKI, PubMed, Embase and The Cochrane Libraray databases, relevant information on the treatment of atopic dermatitis with Abrocitinib, Upadacitinib and Baricitinib was collected, and quantitative scoring was performed from five dimensions including pharmaceutical properties, efficacy, safety, economy and other attributes, and the recommendation level was divided according to the scoring results.

RESULTS The final scores of three JAK inhibitors were 72.19 points for Abrocitinib, 77.50 points for Upadacitinib and 67.16 points for Baricitinib. The scores of Abrocitinib and Upadacitinib were more than 70 points, and it was recommended to enter the drug use catalog of medical institutions. The scores of Baricitinib was between 60 and 70 points, and it was weakly recommended or not recommended to enter the drug use catalog of medical institutions. Upadacitinib had a strong advantage in efficacy, with a score of 25.00; none of the three JAK inhibitors had significant advantages in pharmaceutical properties, safety, economy, and other attributes.

CONCLUSION The practice of drug selection can provide practical experience for medical institutions to evaluate and select drug, and provide evidence-based medical evidence for selection of oral JAK inhibitors for atopic dermatitis patients.